Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Wilby, Kyle John; Lau, Tim T Y; Gilchrist, Seth; Ensom, Mary H H

doi:10.1345/aph.1aq634

Cited by 28 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also seen a paradigm shift in the availability of these vaccines in the developing world through the efforts of the Gavi alliance and WHO (Fund V). In addition, new vaccines are being developed to target diseases whose primary impact is in developing countries such as the malaria (Wilby et al, 2012) and meningococcal A vaccines (Kristiansen et al, 2013). These changes in technology and the distribution of vaccines have saved many lives and have the potential to save millions more if widespread vaccine use is sustained.…”

mentioning

confidence: 99%

Recognizing the Importance of Vaccine Confidence

Black

2016

EBioMedicine

View full text Add to dashboard Cite

mentioning

confidence: 99%

Recognizing the Importance of Vaccine Confidence

Black

2016

EBioMedicine

View full text Add to dashboard Cite

“…15 Furthermore, the partially validated data method can provide a possible solution to remedy the potential misclassification of ordinal variables after the study is completed. 35 It also enables better use of the budget and time for a clinical trial or other prevalence studies. The optimal proportion of n∕N, given a set budget, would be another practical and meaningful follow-up study.…”

Section: Discussionmentioning

confidence: 99%

“…A new vaccine named Mosquirix has been developed to prevent of P. falciparum (asexual forms) malaria. 35 In contrast, prevention methods that target P. falciparum (sexual forms) have received more attention. 36 One important reason is that the sexual form is related to the transmission of malaria, and monitoring the presence of the sexual form is vital to controlling malaria at a population level and decreasing the community's burden of malaria.…”

Section: An Example With An Unknown Misclassification Matrixmentioning

confidence: 99%

Noninferiority testing for matched‐pair ordinal data with misclassification

Han

Poon

2019

Statistics in Medicine

View full text Add to dashboard Cite

New treatments that are noninferior or equivalent to—but not necessarily superior to—the reference treatment may still be beneficial to patients because they have fewer side effects, are more convenient, take less time, or cost less. The noninferiority test is widely used in medical research to provide guidance in such situation. In addition, categorical variables are frequently encountered in medical research, such as in studies involving patient‐reported outcomes. In this paper, we develop a noninferiority testing procedure for correlated ordinal categorical variables based on a paired design with a latent normal distribution approach. Misclassification is frequently encountered in the collection of ordinal categorical data; therefore, we further extend the procedure to account for misclassification using information in the partially validated data. Simulation studies are conducted to investigate the accuracy of the estimates, the type I error rates, and the power of the proposed procedure. Finally, we analyze one substantive example to demonstrate the utility of the proposed approach.

show abstract

“…In July 2015, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion for the "candidate vaccine" Mosquirix. The vaccine is awaiting the final response from the WHO and African health authorities, with whose approval Phase III of its examination has been conducted [29]. The latest information favors the vaccine which consists of the central repeat the C-terminal domain of Plasmodium falciparum circumsporozoite protein, fused to hepatitis B virus surface antigen (HBsAg) in a 1:4 ratio.…”

Section: Chemoprophylaxismentioning

confidence: 99%

Malaria in the 21st century - still a threatening problem

Čanović

Jovicić

Pavlović³

2019

Srp Arh Celok Lek

View full text Add to dashboard Cite

There are six parasite species (P. falciparum, P. vivax, P. ovale curtisi, P. ovale wallikeri, P. malariae, and P. knowlesi) that cause malaria in humans. P. falciparum is responsible for most malaria-related deaths globally. P. vivax is the dominant malaria parasite in most countries outside of the Sub-Saharan Africa. In 2016, 91 countries reported a total of 216 million cases of malaria. The global tally of malaria deaths reached 445,000. In 2016, 24 cases of imported malaria were registered in the Republic of Serbia, with an incidence of 0.33/100,000. According to the World Health Organization recommendations, every suspected malaria case should be confirmed by microscopy or a rapid diagnostic test before treatment. The main stone of antimalarial therapy should be artemisinin-based combinations. Since malaria occurs in Europe as an imported (though rarely also autochthonous and a hospital-borne infection), the objective of this paper is to point out current problems and attitudes in the diagnosis and treatment of malaria, without entering the data field significant for professionals (infectologists, epidemiologists, intensivists).

show abstract

Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Cited by 28 publications

References 16 publications

Recognizing the Importance of Vaccine Confidence

Recognizing the Importance of Vaccine Confidence

Noninferiority testing for matched‐pair ordinal data with misclassification

Malaria in the 21st century - still a threatening problem

Contact Info

Product

Resources

About